Vanguard Group Inc. Grows Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Vanguard Group Inc. boosted its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 1.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,396,285 shares of the medical instruments supplier’s stock after purchasing an additional 64,367 shares during the period. Vanguard Group Inc. owned about 7.34% of OraSure Technologies worth $32,000,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OSUR. Earnest Partners LLC lifted its holdings in shares of OraSure Technologies by 5.2% during the 1st quarter. Earnest Partners LLC now owns 5,123,334 shares of the medical instruments supplier’s stock valued at $34,736,000 after buying an additional 251,955 shares during the period. State Street Corp increased its position in OraSure Technologies by 1.9% in the second quarter. State Street Corp now owns 3,440,307 shares of the medical instruments supplier’s stock worth $9,323,000 after buying an additional 63,392 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in OraSure Technologies by 6.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,156,930 shares of the medical instruments supplier’s stock worth $21,405,000 after acquiring an additional 205,126 shares during the period. Neuberger Berman Group LLC increased its stake in shares of OraSure Technologies by 8.7% in the third quarter. Neuberger Berman Group LLC now owns 2,953,375 shares of the medical instruments supplier’s stock worth $11,214,000 after purchasing an additional 236,827 shares in the last quarter. Finally, Cannell Capital LLC raised its position in shares of OraSure Technologies by 36.5% during the 3rd quarter. Cannell Capital LLC now owns 2,820,591 shares of the medical instruments supplier’s stock valued at $16,726,000 after purchasing an additional 753,901 shares during the period. Hedge funds and other institutional investors own 93.50% of the company’s stock.

OraSure Technologies Stock Performance

Shares of NASDAQ:OSUR opened at $5.77 on Friday. The firm has a market cap of $441.46 million, a price-to-earnings ratio of 8.01 and a beta of 0.15. The firm has a fifty day moving average price of $6.76 and a 200 day moving average price of $6.84. OraSure Technologies, Inc. has a fifty-two week low of $4.38 and a fifty-two week high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the consensus estimate of $0.13 by $0.09. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The business had revenue of $75.88 million during the quarter, compared to the consensus estimate of $74.13 million. During the same quarter in the prior year, the firm earned $0.21 EPS. The business’s revenue was down 38.3% on a year-over-year basis. As a group, research analysts predict that OraSure Technologies, Inc. will post -0.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Evercore ISI cut their price target on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research note on Thursday, April 4th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.38.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.